articleTop 1% cited
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
The Lancet Oncology · 2011 · Vol. 12(8) · pp. 735–742
Caicun Zhou✉(Shanghai Pulmonary Hospital)Yi‐Long Wu(Guangdong Academy of Medical Sciences)Gongyan Chen(Harbin Medical University)Jifeng Feng(Jiangsu Cancer Hospital)Xiaoqing Liu(Academy of Military Medical Sciences)Changli Wang(Tianjin Medical University Cancer Institute and Hospital)Shucai Zhang(Capital Medical University)Jie Wang(Peking University)Songwen Zhou(Shanghai Pulmonary Hospital)Shengxiang Ren(Shanghai Pulmonary Hospital)Shun Lü(Shanghai Jiao Tong University)Li Zhang(Sun Yat-sen University Cancer Center)Chengping Hu(Central South University)Chunhong Hu(Second Xiangya Hospital of Central South University)Yi Luo(Hunan Cancer Hospital)Lei Chen(Cancer Hospital of Shantou University Medical College)Ming Ye(Renji Hospital)Jianan Huang(First Affiliated Hospital of Soochow University)Xiuyi Zhi(Capital Medical University)Yiping Zhang(Zhejiang Cancer Hospital)Qingyu Xiu(Second Military Medical University)Jun Ma(Harbin Institute of Petroleum)L Zhang(Sun Yat-sen University Cancer Center)Changxuan You(Nanfang Hospital)
Lung Cancer Treatments and MutationsLung Cancer Research StudiesColorectal Cancer Treatments and StudiesMedicineErlotinibInternal medicineLung cancerGemcitabineOncologyTolerabilityCarboplatinHazard ratioT790M
MeSH terms
Erlotinib HydrochlorideGemcitabineAdministration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungChinaDeoxycytidineFemaleHumansLung NeoplasmsMaleMiddle AgedMutation
Citations
4,075
FWCI
231.16
field-weighted impact
References
25
Percentile
100%
vs. same field & year
Citations per year
Cited by
Targeting RTK Signaling Pathways in Cancer
Cancers · 2015 · 375 citations
The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Oncotarget · 2016 · 768 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
The Lancet Oncology · 2015 · 1,573 citations
Establishing the Diagnosis of Lung Cancer
CHEST Journal · 2013 · 1,052 citations
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
The Lancet Oncology · 2012 · 5,500 citations
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
The Lancet Oncology · 2014 · 1,963 citations
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Mayo Clinic Proceedings · 2019 · 2,172 citations
References
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
International Journal of Cancer · 2010 · 21,378 citations
The National Comprehensive Cancer Network
Cancer · 1998 · 16,869 citations
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
The Lancet Oncology · 2009 · 4,101 citations
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
JNCI Journal of the National Cancer Institute · 2005 · 2,385 citations
Cancer Statistics, 2010
CA A Cancer Journal for Clinicians · 2010 · 12,602 citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
New England Journal of Medicine · 2009 · 8,201 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.